Lupin

Lupin Limited (BSE: 500257 | NSE: LUPIN) is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Founded in 1968 by Desh Bandhu Gupta, Lupin has grown to become one of the largest generic pharmaceutical companies globally by revenue. The company started as a small vitamin manufacturing unit and has since expanded its portfolio to include generic drugs, branded drugs, and specialty pharmaceuticals. Lupin is listed on the Bombay Stock Exchange and National Stock Exchange of India.

Lupin's key products and services include:

• Generic formulations across major therapeutic areas like cardiovascular, diabetes, respiratory, anti-infective, gastrointestinal, and central nervous system disorders

• Active Pharmaceutical Ingredients (APIs)

• Branded generics in India and other emerging markets

• Biosimilars including Etanercept for treating inflammatory diseases

• Complex generics like inhalation products and injectables

• Over-the-counter (OTC) consumer health products

• Digital healthcare solutions like mobile apps for disease management

Lupin has a significant global presence with operations in over 100 countries. The company has 15 manufacturing facilities across India, the US, Brazil and Mexico. It has seven research centers focused on developing complex generics and biosimilars. In FY2023, Lupin invested 7.9% of its revenue in research and development. The company has a workforce of over 20,000 employees globally. Lupin continues to focus on expanding its complex generics portfolio and digital healthcare initiatives to drive future growth.